{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:38:58Z","timestamp":1792571938491,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":215,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) develops over years, creating an opportunity for interventions that target modifiable risk factors before the onset of clinical dementia. Here we applied a federated electronic health record (EHR) system encompassing over 29 million de-identified patients toward a target-trial emulation framework involving 153,412 adults aged 50\u2009years or older with at least one documented AD risk factor. New users of glucagon-like peptide-1 (GLP-1)\u2013based incretin therapy were compared with new users of non-GLP-1 antidiabetic medications after a 12-month washout, with 1:1 propensity-score matching on 30 baseline variables and additional exact matching on index year of therapy initiation and 5-year age band. In the primary matched cohort, 28,901 patients per arm, incretin initiation was associated with lower first recorded AD diagnosis (hazard ratio [HR] 0.46, 95% confidence interval [CI] 0.29\u20130.73, q\u2009=\u20090.003), all-cause dementia (HR 0.66 [0.55\u20130.79], q\u2009&amp;lt;\u20090.001), and all-cause mortality (HR 0.46 [0.37\u20130.58], q\u2009&amp;lt;\u20090.001), with directionally-lower Mild Cognitive Impairment (HR 0.76 [0.61\u20130.94], q\u2009=\u20090.135) and Alzheimer\u2019s-related medication initiation (HR 0.82 [0.65\u20131.03], q\u2009=\u20090.217). The AD diagnosis mitigation signal was independently reproduced for semaglutide (HR 0.56; N\u2009=\u200923,675 per arm; q\u2009=\u20090.02), with the directionally consistent tirzepatide point estimate (HR 0.60) not reaching significance. GLP-1 RA initiation was also associated with substantially lower (all q\u2009&amp;lt;\u20090.001) incidence of heart failure (HR 0.50 [0.45\u20130.55]), cardiomyopathy (HR 0.38 [0.31\u20130.47]), major adverse cardiovascular events (HR 0.74 [0.67\u20130.82]), acute kidney injury (HR 0.67 [0.67\u20130.74]), and chronic kidney disease (HR 0.68 [0.62\u20130.75]). Negative-control outcomes showed no significant separation (all q\u2009&amp;gt;\u20090.45), including allergic rhinitis (HR 0.96 [0.87\u20131.07]), hemorrhoids (HR 1.07 [0.95\u20131.21]), and inguinal hernia (HR 1.39 [0.89\u20132.18]). Stricter two-code ICD definitions supported lower first recorded AD diagnosis in the incretin arm (HR 0.51 [0.29\u20130.89], q\u2009=\u20090.018) and lower first recorded all-cause dementia diagnosis (HR 0.68 [0.54\u20130.85], q\u2009=\u20090.003). In 12-month landmark analyses among semaglutide initiators, \u22655% weight-loss responders had lower 3-year AD cumulative incidence than non-responders after matching (0.07% vs. 0.40%; incidence ratio 5.76; P\u2009=\u2009.036), although this was not significant in the hazard-ratio model (HR 0.54, P\u2009=\u2009.39). Sustained-dose stratification showed no comparable gradient (high-dose vs. low-dose 0.30% vs. 0.14%; HR 2.77; P\u2009=\u2009.38), with \u226412 AD events per group. The weight-loss-specific pattern did not extend to all-cause dementia: weight-loss responders and non-responders had similar 3-year cumulative incidence (1.54% vs. 1.70%; HR 0.87, P\u2009=\u2009.53). Initiation of GLP-1 receptor agonist therapy in adults with documented AD risk factors was associated with lower recorded incidence of AD, dementia, mortality, and multiple cardiovascular and renal outcomes in this observational target-trial emulation. These findings support the hypothesis that earlier incretin therapy may contribute to AD risk modification through upstream cardiometabolic pathways, while prospective randomized prevention studies will be required to determine causality, underlying biological mechanisms, and optimal treatment timing.<\/jats:p>","DOI":"10.1093\/biomethods\/bpag043","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:02:07Z","timestamp":1785585727000},"source":"Crossref","is-referenced-by-count":0,"title":["GLP-1\u2013based incretin therapy is associated with lower incident Alzheimer\u2019s disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk"],"prefix":"10.1093","volume":"11","author":[{"given":"Karthik","family":"Murugadoss","sequence":"first","affiliation":[{"name":"nference , 1 Main Street, East Arcade building , Cambridge, MA,","place":["United States"]},{"name":"Metabolism Agentic Intelligence Atlas (MAIA) , Cambridge, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2819-3214","authenticated-orcid":false,"given":"A J","family":"Venkatakrishnan","sequence":"additional","affiliation":[{"name":"nference , 1 Main Street, East Arcade building , Cambridge, MA,","place":["United States"]},{"name":"Metabolism Agentic Intelligence Atlas (MAIA) , Cambridge, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-9211","authenticated-orcid":false,"given":"Venky","family":"Soundararajan","sequence":"additional","affiliation":[{"name":"nference , 1 Main Street, East Arcade building , Cambridge, MA,","place":["United States"]},{"name":"Metabolism Agentic Intelligence Atlas (MAIA) , Cambridge, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"2026102103480735700_bpag043-B1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","journal-title":"Lancet Public Health"},{"key":"2026102103480735700_bpag043-B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102103480735700_bpag043-B3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"2026102103480735700_bpag043-B4","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1007\/s00125-005-0023-4","article-title":"Cognitive decline and dementia in diabetes\u2014systematic overview of prospective observational studies","volume":"48","author":"Cukierman","year":"2005","journal-title":"Diabetologia"},{"key":"2026102103480735700_bpag043-B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2026102103480735700_bpag043-B6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026102103480735700_bpag043-B7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026102103480735700_bpag043-B8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102103480735700_bpag043-B9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102103480735700_bpag043-B10","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102103480735700_bpag043-B11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102103480735700_bpag043-B12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102103480735700_bpag043-B13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102103480735700_bpag043-B14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"2026102103480735700_bpag043-B15","doi-asserted-by":"publisher","first-page":"e12268","DOI":"10.1002\/trc2.12268","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement (N. Y.)"},{"key":"2026102103480735700_bpag043-B16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","article-title":"Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial","volume":"32","author":"Edison","year":"2026","journal-title":"Nat Med"},{"key":"2026102103480735700_bpag043-B17","doi-asserted-by":"publisher","first-page":"e23316","DOI":"10.1200\/JCO.2024.42.16_suppl.e23316","article-title":"Clinical nSights: a software platform to accelerate real world oncology analyzes","volume":"42","author":"Lenehan","year":"2024","journal-title":"JCO"},{"key":"2026102103480735700_bpag043-B18","doi-asserted-by":"publisher","first-page":"pgag171","DOI":"10.1093\/pnasnexus\/pgag171","article-title":"Weight-loss dynamics with tirzepatide versus semaglutide","volume":"5","author":"Venkatakrishnan","year":"2026","journal-title":"PNAS Nexus"},{"key":"2026102103480735700_bpag043-B19","doi-asserted-by":"crossref","first-page":"bpag020","DOI":"10.1093\/biomethods\/bpag020","article-title":"Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network","volume":"11","author":"Murugadoss","year":"2026","journal-title":"Biol. Methods Protoc"},{"key":"2026102103480735700_bpag043-B20","doi-asserted-by":"crossref","first-page":"bpag021","DOI":"10.1093\/biomethods\/bpag021","article-title":"Decoding the hallmarks of GLP-1 RA weight-loss super-responders","volume":"11","author":"Venkatakrishnan","year":"2026","journal-title":"Biol. Methods Protoc"},{"key":"2026102103480735700_bpag043-B21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"2026102103480735700_bpag043-B22","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026102103480735700_bpag043-B23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"2026102103480735700_bpag043-B24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2026102103480735700_bpag043-B25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2026102103480735700_bpag043-B26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"2026102103480735700_bpag043-B27","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2026102103480735700_bpag043-B28","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.6841482","author":"Murugadoss","year":"2026","journal-title":"Functional-vs-Cognitive Decline Heterogeneity in Alzheimer\u2019s Disease Revealed by LLM-Curation of Decades of Clinical Notes Has Implications for Semaglutide Trial Design"},{"key":"2026102103480735700_bpag043-B29","doi-asserted-by":"publisher","first-page":"e0000685","DOI":"10.1371\/journal.pdig.0000685","article-title":"Evaluating Large Language Models in extracting cognitive exam dates and scores","volume":"3","author":"Zhang","year":"2024","journal-title":"PLOS Digit. Health"},{"key":"2026102103480735700_bpag043-B30","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202606.0635.v1","article-title":"Semaglutide use linked to lower COVID-19 and influenza severity with better cardiovascular, pulmonary, renal outcomes after pandemic or seasonal infection","author":"Matson","year":"2026","journal-title":"Preprints"},{"key":"2026102103480735700_bpag043-B31","doi-asserted-by":"publisher","author":"Murugadoss","DOI":"10.64898\/2026.04.23.26351609"},{"key":"2026102103480735700_bpag043-B32","doi-asserted-by":"publisher","author":"Matson","DOI":"10.20944\/preprints202606.0638.v1"},{"key":"2026102103480735700_bpag043-B33","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202606.0682.v1","article-title":"Auditable LLM curation of clinical notes refines GLP-1 initiation, persistence ascertainment and compounding use beyond prescription records","author":"Varma","year":"2026","journal-title":"Preprints"},{"key":"2026102103480735700_bpag043-B34","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-9407186\/v1","article-title":"Soundararajan, V. Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping","author":"Murugadoss","year":"2026","journal-title":"Research Square"},{"key":"2026102103480735700_bpag043-B35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/biomet\/34.1-2.28","article-title":"The generalisation of student\u2019s problems when several different population variances are involved","volume":"34","author":"Welch","year":"1947","journal-title":"Biometrika"},{"key":"2026102103480735700_bpag043-B36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2026102103480735700_bpag043-B37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2026102103480735700_bpag043-B38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2026102103480735700_bpag043-B39","doi-asserted-by":"publisher","first-page":"100255","DOI":"10.1016\/j.patter.2021.100255","article-title":"Building a best-in-class automated de-identification tool for electronic health records through ensemble learning","volume":"2","author":"Murugadoss","year":"2021","journal-title":"Patterns (N. Y.)"},{"key":"2026102103480735700_bpag043-B40","doi-asserted-by":"publisher","author":"Murugadoss","DOI":"10.1101\/2024.06.20.24308896"},{"key":"2026102103480735700_bpag043-B41","doi-asserted-by":"publisher","author":"Murugadoss","DOI":"10.64898\/2026.04.02.26350077"},{"key":"2026102103480735700_bpag043-B42","doi-asserted-by":"publisher","author":"Murugadoss","DOI":"10.20944\/preprints202606.0636.v1"},{"key":"2026102103480735700_bpag043-B43","doi-asserted-by":"publisher","author":"Murugadoss","DOI":"10.64898\/2026.04.16.26351060"},{"key":"2026102103480735700_bpag043-B44","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102103480735700_bpag043-B45","doi-asserted-by":"publisher","first-page":"e004902","DOI":"10.1136\/bmjdrc-2025-004902","article-title":"Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes","volume":"13","author":"Sun","year":"2025","journal-title":"BMJ Open Diab Res Care"},{"key":"2026102103480735700_bpag043-B46","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag032","article-title":"GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD","author":"Lee","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"2026102103480735700_bpag043-B47","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/S0140-6736(26)00459-9","article-title":"Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer\u2019s disease (evoke and evoke\u00b1): two phase 3, randomised, placebo-controlled trials","volume":"407","author":"Cummings","year":"2026","journal-title":"Lancet"},{"key":"2026102103480735700_bpag043-B48","doi-asserted-by":"publisher","DOI":"10.1038\/s44355-026-00076-w","article-title":"Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns","volume":"3","author":"Venkatakrishnan","year":"2026","journal-title":"Npj Gut Liver"},{"key":"2026102103480735700_bpag043-B49","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1177\/13872877251351329","article-title":"Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: a real-world target trial emulation study","volume":"106","author":"Wang","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"2026102103480735700_bpag043-B50","doi-asserted-by":"publisher","first-page":"109306","DOI":"10.1016\/j.jdiacomp.2026.109306","article-title":"Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer\u2019s disease in type 2 diabetes: a real-world, retrospective cohort study","volume":"40","author":"da Silva","year":"2026","journal-title":"J Diabetes Complications"}],"container-title":["Biology Methods and Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biomethods\/advance-article-pdf\/doi\/10.1093\/biomethods\/bpag043\/70473947\/bpag043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomethods\/article-pdf\/11\/1\/bpag043\/70473947\/bpag043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomethods\/article-pdf\/11\/1\/bpag043\/70473947\/bpag043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:48:13Z","timestamp":1792568893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biomethods\/article\/doi\/10.1093\/biomethods\/bpag043\/8750604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/biomethods\/bpag043","relation":{},"ISSN":["2396-8923"],"issn-type":[{"value":"2396-8923","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"bpag043"}}